

Beyond Ozempic: The Probiotic That Finally Stops Chocolate (& Food) Binges. Join Our Science Trial. (#72)
35 snips Oct 28, 2024
Dr. Colleen Cutcliffe, CEO of Pendulum Therapeutics and an expert in biochemistry, reveals a groundbreaking probiotic that stimulates natural GLP-1 production. She shares why traditional GLP-1 drugs like Ozempic are being challenged by this new approach. Listeners learn about impressive trial results showing reduced food cravings and the complexities of probiotic production. Colleen also discusses the importance of keystone strains in the microbiome and the potential benefits for managing obesity and diabetes.
AI Snips
Chapters
Transcript
Episode notes
Vast Microbiome Potential
- Less than 1% of the entire human microbiome is represented in current probiotics.
- There's significant potential for novel interventions.
Manufacturing Challenges
- Existing probiotic manufacturers couldn't grow Pendulum's strains due to their oxygen-free requirement.
- This led to Pendulum developing their own novel, oxygen-free manufacturing process.
Advanced Probiotic Analysis
- Instead of standard colony forming units (CFUs), Pendulum uses flow cytometry to analyze their probiotics.
- This provides detailed information about live, dead, and partially dead cells, plus small molecules and butyrate production levels.